



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	December 3, 2015 November 29, 2016

REXULTI[®] (brexpiprazole)

LENGTH OF AUTHORIZATION: Up to one year

CLINICAL NOTES: Brexpiprazole (Rexulti[®]) is an atypical antipsychotic indicated for the treatment of schizophrenia and for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).

REVIEW CRITERIA:

- Patient must be ≥ 18 years old.
- Patient must have a diagnosis of schizophrenia or major depressive disorder.
- For the treatment of schizophrenia, patient must have a history of trial and failure of at least:
 - Two preferred atypical antipsychotics with a minimum 30-day treatment period with each agent.
- For the adjunctive treatment of major depressive disorder, patient must have a history of trial and failure with a minimum of two antidepressants drug within the past 365 days; **AND**
 - Documentation that brexpiprazole (Rexulti[®]) will be used concurrently with an antidepressant. (Failure can be defined as inefficacy or intolerability, but not non-compliance).

DOSING & ADMINISTRATION:

Major Depression Disorder: Start at 0.5mg-1mg by mouth once daily. The dose may be increased at weekly intervals to a maximum of 3mg per day. The recommended dose is 2mg daily.

Schizophrenia: Start at 1mg per day for 4 days, increase to 2mg daily for 3 days, then increase to 4mg once daily. Maximum dose is 4mg daily.

Dosage Forms available: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, and 4mg tablets